[1] GRILZ E,POSCH F,NOPP S,et al.Relative risk of arterial and venous thromboembolism in persons with cancer vs.persons without cancer-a nationwide analysis[J].Eur Heart J,2021,42(23):2299-2307.
[2] SINGH G,RATHI AK,SINGH K,et al.Venous thromboembolism in cancer patients-magnitude of problem,approach,and management[J].Indian J Cancer,2017,54(1):308-312.
[3] RONDON AMR,KROONE C,KAPTEIJN MY,et al.Role of tissue factor in tumor progression and cancer-associated thrombosis[J].Semin Thromb Hemost,2019,45(4):396-412.
[4] KHORANA AA,FRANCIS CW,CULAKOVA E,et al.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J].J Thromb Haemost,2007,5(3):632-634.
[5] DEBBIE JIANG MD,ALFRED LAN LEE MD.Thrombotic risk from chemotherapy and other cancer therapies[J].Cancer Treat Res,2019,179:87-101.
[6] GIUSTOZZI M,CURCIO A,WEIJS B,et al.Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer[J].Thromb Haemost,2020,120(5):847-856.
[7] HASLAM A,PRASAD V.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs[J].JAMA Netw Open,2019,2(5):1-9.
[8] VADDEPALLY RK,KHAREL P,PANDEY R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence[J].Cancers (Basel),2020,12(3):1-19.
[9] BAGCHI S,YUAN R,ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance[J].Annu Rev Pathol,2021,16:223-249.
[10] KARTOLO A,YEUNG C,MOFFAT GT,et al.Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors[J].Immunotherapy,2022,14(1):23-30.
[11] WANG TF,KHORANA AA,CARRIAER M.Thrombotic complications associated with immune checkpoint inhibitors[J].Cancers (Basel),2021,13(18):1-12.
[12] KUNIMASA K,NISHINO K,KIMURA M,et al.Pembrolizumab-induced acute thrombosis:A case report[J].Medicine (Baltimore),2018,97(20):1-3.
[13] TSUKAMOTO J,MONTEIRO M,VALE S,et al.Thromboembolic events related to treatment with checkpoint inhibitors:report of two cases[J].Case Rep Oncol,2018,11(3):648-653.
[14] ABBAS W,DIXIT G,RAO RR,et al.Immunotherapy-induced acute pulmonary thromboembolism:A case report[J].South Asian J Cancer,2019,8(3):172-182.
[15] HERBST RS,BAAS P,KIM DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[16] CARBONE DP,RECK M,PAZ-ARES L,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J].N Engl J Med,2017,376(25):2415-2426.
[17] SOCINSKI MA,JOTTE RM,CAPPUZZO F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J].N Engl J Med,2018,378(24):2288-2301.
[18] HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J].N Engl J Med,2019,381(21):2020-2031.
[19] TARHINI AA,LEE SJ,HODI FS,et al.Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma:North American Intergroup E1609[J].J Clin Oncol,2020,38(6):567-575.
[20] SOLINAS C,SABA L,SGANZERLA P,et al.Venous and arterial thromboembolic events with immune checkpoint inhibitors:A systematic review[J].Thromb Res,2020,196:444-453.
[21] PETRELLI F,SOLINAS C.Reply to the letter to the editor ' Reply to Solinas et al,venous and arterial thromboembolic events with immune checkpoint inhibitors:A systematic review' by Frere et al[J].Thromb Res,2021,208:217-218.
[22] GOEL A,KHORANA A,KARTIKA T,et al.Assessing the risk of thromboembolism in cancer patients receiving immunotherapy[J].Eur J Haematol,2022,108(4):271-277.
[23] SUSSMAN TA,LI H,HOBBS B,et al.Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival[J].J Immunother Cancer,2021,9(1):1-8.
[24] DESCHENES-SIMARD X,RICHARD C,GALLAND L,et al.Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer:A retrospective multicentric cohort study[J].Thromb Res,2021,205:29-39.
[25] ROOPKUMAR J,SWAIDANI S,KIM AS,et al.Increased incidence of venous thromboembolism with cancer immunotherapy[J].Med (N Y),2021,2(4):423-434.
[26] GUVEN DC,AKSUN MS,SAHIN TK,et al.Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy[J].Support Care Cancer,2021,29(9):5417-5423.
[27] GONG J,DROBNI ZD,ALVIl RM,et al.Immune checkpoint inhibitors for cancer and venous thromboembolic events[J].Eur J Cancer,2021,158:99-110.
[28] MOIK F,CHAN WE,WIEDEMANN S,et al.Incidence,risk factors,and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J].Blood,2021,137(12):1669-1678.
[29] GUTIERREZ-SAINZ L,MARTINEZ-MARIN V,VINAL D,et al.Incidence of venous thromboembolic events in cancer patients receiving immunotherapy:a single-institution experience[J].Clin Transl Oncol,2021,23(6):1245-1252.
[30] CARRIER M,KHORANA AA,ZWICKER JI,et al.Venous thromboembolism in cancer clinical trials:recommendation for standardized reporting and analysis[J].J Thromb Haemost,2012,10(12):2599-2601.
[31] BAR J,MARKEL G,GOTTFRIED T,et al.Acute vascular events as a possibly related adverse event of immunotherapy:a single-institute retrospective study[J].Eur J Cancer,2019,120:122-131.
[32] ICHT O,DARZI N,SHIMONY S,et al.Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors[J].J Thromb Haemost,2021,19(5):1250-1258.
[33] MULDER FI,HORVATH-PUHO E,VAN ES N,et al.Venous thromboembolism in cancer patients:a population-based cohort study[J].Blood,2021,137(14):1959-1969.
[34] LI H,SUN X,SUN D,et al.Thromboembolic events associated with immune checkpoint inhibitors:A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database[J].Int Immunopharmacol,2021,98:1-7.
[35] KARTOLO A,YEUNG C,MOFFAT GT,et al.Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors[J].Immunotherapy,2022,14(1):23-30.
[36] RONDON AMR,KROONE C,KAPTEIJN MY,et al.Role of tissue factor in tumor progression and cancer-associated thrombosis[J].Semin Thromb Hemost,2019,45(4):396-412.
[37] HORIO Y,TAKAMATSU K,TAMANOI D,et al.Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient[J].Eur J Immunol,2018,48(10):1764-1767.
[38] SATO R,IMAMURA K,SAKATA S,et al.Disorder of coagulation-fibrinolysis system:An emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies[J].J Clin Med,2019,8(6):1-22.
[39] COCHAIN C,CHAUDHARI SM,KOCH M,et al.Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice[J].PLoS One,2014,9(4):1-10.
[40] BU DX,TARRIO M,MAGANTO-GARCIA E,et al.Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation[J].Arterioscler Thromb Vasc Biol,2011,31(5):1100-1107.
[41] SACCHI A,GRASSI G,NOTARI S,et al.Expansion of myeloid derived suppressor cells contributes to platelet activation by l-arginine deprivation during SARS-CoV-2 infection[J].Cells,2021,10(8):1-7.
[42] ALFARO C,TEIJEIRA A,ONATE C,et al.Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)[J].Clin Cancer Res,2016,22(15):3924-3936.
[43] KEY NS,KHORANA AA,KUDERER NM,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update[J].J Clin Oncol,2020,38(5):496-520.
[44] KEWAN T,KO T,FLORES M,et al.Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors[J].Eur J Haematol,2021,106(5):682-688.
[45] CARRIER M,ABOU-NASSAR K,MALLICK R,et al.Apixaban to prevent venous thromboembolism in patients with cancer[J].N Engl J Med,2019,380(8):711-719.
[46] KHORANA AA,SOFF GA,KAKKAR AK,et al.Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer[J].N Engl J Med,2019,380(8):720-728.
[47] KHORANA AA,NOBLE S,LEE AYY,et al.Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH[J].J Thromb Haemost,2018,16(9):1891-1894.
[48] 马军,秦叔逵,吴一龙,等.肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J].中国肿瘤临床,2019,46(13):653-660.
MA J,QIN SK,WU YL,et al.Guidelines for the prevention and treatment of tumor-associated venous thromboembolism (2019 edition)[J].Chin J Clin Oncol,2019,46(13):653-660.
[49] MAO Z,JIA X,JIANG P,et al.Effect of concomitant use of analgesics on prognosis in patients treated with immune checkpoint inhibitors:A systematic review and Meta-analysis[J].Front Immunol,2022,13:1-12.